Drug Trial Radar · NCT02633527
Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD
Last checked: Nov 20, 2026Latest source record: Oct 27, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
222
Actual
Start
Feb 1, 2016
Primary completion
Jul 25, 2016
Study completion Jul 25, 2016
Sponsor
- Lead sponsor
- Supernus Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 17, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a randomized, double-blind, placebo-controlled, multicenter, 5-arm, parallel-group, dose-ranging study to assess the efficacy and safety of SPN-812 (Viloxazine Extended-release Capsule) in children 6-12 years of age with ADHD.
Conditions
- Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
PlaceboDrug
Placebo was administered once daily
100mg SPN-812Drug
100mg SPN-812 was administered once daily and compared to placebo
200mg SPN-812Drug
200mg SPN-812 was administered once daily and compared to placebo
300mg SPN-812Drug
300mg SPN-812 was administered once daily and compared to placebo
400mg SPN-812Drug
400mg SPN-812 was administered once daily and compared to placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Efficacy of SPN-812 on the Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition (ADHD-RS-IV)Time frame: Baseline to Week 8 (End of Study)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Florida Clinical Research Center, LLC
Maitland, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.